ABU DHABI, UAE, Nov. 30, 2024 /PRNewswire/ — ADGM, the international financial centre (“IFC”) of Abu Dhabi, announced another quarter of unprecedented growth, with exceptional achievements for the third quarter (“Q3”) of 2024 across key metrics. The results underscore ADGM’s pivotal role in Abu Dhabi’s strategic ambition to diversify its economy and solidify its position as a premier global destination for finance, investment, and innovation. ADGM continues to align with Abu Dhabi’s economic growth, which registered a 6.6% growth in non-oil GDP, in the Q2 of 2024.

His Excellency Ahmed Jasim Al Zaabi, the Chairman of ADGM, remarked, “Our record-breaking achievements in Q3 exemplify the appeal of ADGM’s world-class ecosystem that brings together a stable regulatory environment, strategic location and ease of doing business. The continued influx of businesses and investors into ADGM highlights Abu Dhabi’s competitive advantage in the global financial industry and the growth of the Falcon Economy. As we pave the ‘Path to Forward’, we aim to continue building on this momentum to deliver further growth and innovation that benefits not just Abu Dhabi and the UAE, but the wider financial community.”

Asset Management Leads Growth

ADGM recorded a substantial increase of 215% in total Assets Under Management (AUM) in Q3 2024 compared to Q3 2023, demonstrating its rapid ascent as a top asset management hub in the MENA region. This growth highlights ADGM’s ability to attract high-calibre asset managers, investment funds, and private equity firms, establishing it as a go-to location for institutional investors worldwide. This is also reflected in the growth of the total fund and asset managers, which reached 128, managing 156 funds, as of the end of Q3 2024.

Joiners during the Q3 of 2024 include PGIM, Nuveen, Elysium Management, Stonepeak, and Gemcorp Capital.

Surge in New Business Registrations and Expanding Ecosystem

In Q3 of 2024, ADGM saw a 33% rise in the number of newly issued business licences compared to the same period last year. A total of 759 new licences were issued over the period to financial, non-financial and retail firms. The total number of operational entities within ADGM’s jurisdiction jumped to 2,251, an impressive 31% year-on-year growth. The surge reflects strong demand from a diverse range of sectors, including asset management, FinTech, and professional services, within ADGM’s ecosystem.

Furthermore, the workforce within ADGM’s jurisdiction has been steadily increasing with more and more businesses joining its vibrant ecosystem marking an increase of 35% in the overall workforce.

Roadshows Bringing Abu Dhabi to the World

In line with its mission to enhance global connectivity and attract investments, ADGM participated in a series of international roadshows during Q3 of this year. One of the major ones was several high-level engagements in China and Hong Kong to celebrate 40 years of bilateral relations between the UAE and China.  Furthermore, ADGM delegations continued their series of engagements with financial leaders and authorities in the international market covering Singapore, London, Washington DC and New York, bringing the total number of bilateral discussions to more than 150 across key international markets.  

Advertisement

Upcoming Flagship Event

Looking forward, as ADGM nears the end of the 2024 financial year, it is set to host the third edition of its flagship event series, Abu Dhabi Finance Week (ADFW) in December. The event is expected to bring over 20,000 delegates to explore the theme ‘Welcome to the Capital of Capital’.

Logo – https://mma.prnewswire.com/media/1696045/Abu_Dhabi_Global_Market_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/adgms-asset-management-sector-leads-exponential-growth-in-third-quarter-of-2024-302319071.html

• CBC Group and Mubadala acquire UCB’s mature neurology and allergy business in China for US$680 million.
• New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry.
• Strategic acquisition under CBC’s buyout strategy expected to drive significant value creation and positive patient outcomes through CBC’s proven investor-operator approach and solution.

SINGAPORE, Nov. 30, 2024 /PRNewswire/ — CBC Group (“CBC”), Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, has completed the strategic acquisition of global biopharmaceutical company UCB’s mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu Dhabi based global investment company. The acquisition marks another successful transaction under CBC’s buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC’s portfolio within the region’s dynamic pharmaceutical market. The transaction, valued at US$680 million, includes UCB’s well-known brands Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, and the Zhuhai manufacturing site.

The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market size has reached US$33 billion¹. Beyond strengthening CBC’s presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm’s capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap on its proprietary investor-operator approach, deep healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region.

Fu Wei, Chief Executive Officer of CBC Group, said, “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation.”

Named “NeuroGen Pharma”, the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by a deep and experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel into the next phase of growth. NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region.

Combined net sales for the acquired portfolio in this transaction were Euro131 million in 2023. The strategic acquisition builds on CBC’s collaboration with Mubadala, which includes their investment in CBC Healthcare Infrastructure Platform’s (HIP) first life science real assets venture and the joint investment in the US$315 million fundraising round for CBC-backed Hasten, a leading pharmaceutical company.

Mohamed Albadr, Head of Asia at Mubadala, said, “We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system.”

Jean-Christophe Tellier, CEO at UCB, said, “In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China.”

About CBC Group

Headquartered in Singapore, CBC Group is Asia’s largest healthcare-dedicated asset management firm, with an AUM of US$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services.

Advertisement

We are committed to creating lasting value by integrating global innovations and talents. Partnering with the world’s top entrepreneurs and scientists, our unique “investor-operator” approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations, and improve efficiencies in fulfilling unmet medical needs worldwide.

For more information on CBC Group, please visit www.cbridgecap.com/.
Connect with us on LinkedIn (CBC Group).

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About Mubadala

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi. 

Mubadala’s $302 billion (AED 1,111 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates. 

For more information about Mubadala Investment Company, please visit: www.mubadala.com.

View original content:https://www.prnewswire.co.uk/news-releases/cbc-group-completes-strategic-acquisition-of-ucbs-mature-product-portfolio-in-china-302319018.html

Advertisement

SUGAR LAND, Texas, Nov. 29, 2024 /PRNewswire/ — Noble Corporation plc (“Noble”) (NYSE: NE, CSE: NOBLE) today announces changes to its share capital. During the month of November, Noble has repurchased approximately USD 36.6 million of A ordinary shares under its previously announced share repurchase plan at a weighted average price of approximately USD 33.85 per A ordinary share.

During the period since October 31, 2024, 12,536 new A ordinary shares each with a nominal value of USD 0.00001 have been issued.

6,992 new A ordinary shares have been issued to certain holders of warrants as a consequence of the exercise of warrants. The exercise price was USD 19.27 per A ordinary share for 5,845 of the new A ordinary shares, USD 23.13 per A ordinary share for 465 of the new A ordinary shares, USD 124.40 per A ordinary share for 24 of the new A ordinary shares, USD 29.22 per Diamond Offshore Common Stock delivered as Merger Consideration for 648 of the new A ordinary shares and 10 new A ordinary shares were issued as a result of a cashless exercise. The total proceeds to Noble from the warrant exercises amount to approximately USD 0.1 million.

Additionally, 5,544 new A ordinary shares have been issued to certain employees of Noble at no cost as a result of the vesting of restricted stock units.

The new A ordinary shares carry the same rights as the existing A ordinary shares of Noble. The new A ordinary shares will be listed on the New York Stock Exchange as well as admitted to trading and official listing on Nasdaq Copenhagen. 

As a result of the changes, there are a total of 160,382,900 A ordinary shares of Noble issued and outstanding with a nominal value of USD 0.00001 each.

Pursuant to section 32 of the Danish Capital Markets Act, Noble also hereby announces the total nominal value of its issued share capital and the total number of voting rights:

	Number of shares	Number of voting rights	Share capital Advertisement
A ordinary shares of USD 0.00001	160,382,900	160,382,900	1,603.82900
Total	160,382,900	160,382,900	1,603.82900

Noble has received approval from Nasdaq Copenhagen for a voluntary delisting of its shares on Nasdaq Copenhagen 

Noble has on November 18, 2024 received approval from Nasdaq Copenhagen for a voluntary removal from trading and official listing of its shares (in the form of share entitlements) (the “Danish Shares“) on Nasdaq Copenhagen (the “Delisting“).

Advertisement

The last day of trading on Nasdaq Copenhagen will be December 16, 2024 and the Delisting will be effective on December 17, 2024. Following the Delisting, the Danish Shares will no longer be tradable on Nasdaq Copenhagen.

In connection with the Delisting, holders of Danish Shares may:

• Dispose of their Danish Shares on Nasdaq Copenhagen before the Delisting is effective; or
• Convert their Danish Shares to an equivalent number of Noble shares tradeable on the New York Stock Exchange.

Alternatively, holders of Danish Shares may do nothing but will hold an illiquid asset following the Delisting.

For further information about the Delisting or the options available to holders of Danish Shares, see Noble’s announcement of November 14, 2024 regarding the submission of request for removal from trading and official listing on Nasdaq Copenhagen.

Additional information regarding the Delisting can be found on our website at www.noblecorp.com.

About Noble Corporation 
Noble is a leading offshore drilling contractor for the oil and gas industry.  The Company owns and operates one of the most modern, versatile, and technically advanced fleets in the offshore drilling industry.  Noble and its predecessors have been engaged in the contract drilling of oil and gas wells since 1921.  Noble performs, through its subsidiaries, contract drilling services with a fleet of offshore drilling units focused largely on ultra-deepwater and high specification jackup drilling opportunities in both established and emerging regions worldwide.  For further information visit www.noblecorp.com or email [email protected].

IMPORTANT INFORMATION 
This announcement is for information purposes only and does not constitute or contain any invitation, solicitation, recommendation, offer or advice to any person to subscribe for or otherwise acquire or dispose of any securities of Noble.

Certain statements in this announcement, including any attachments hereto, may constitute forward-looking statements. Forward-looking statements are statements (other than statements of historical fact) relating to future events and Noble and its subsidiaries (collectively, the “Noble Group”) anticipated or planned financial and operational performance. The words “targets”, “believes”, “continues”, “expects”, “aims”, “intends”, “plans”, “seeks”, “will”, “may”, “might”, “anticipates”, “would”, “could”, “should”, “estimates”, “projects”, “potentially” or similar expressions or the negatives thereof, identify certain of these forward-looking statements. The absence of these words, however, does not mean that the statements are not forward-looking. Other forward-looking statements can be identified in the context in which the statements are made.

Although Noble believes that the expectations reflected in these forward-looking statements are reasonable as of the date of this announcement, such forward-looking statements are based on Noble’s current expectations, estimates, forecasts, assumptions and projections about the Noble Group’s business and the industry in which the Noble Group operates and/or which has been extracted from publications, reports and other documents prepared by the Noble Group and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other important factors beyond the Noble Group’s control that could cause the Noble Group’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

Any forward-looking statements included in this announcement, including any attachment hereto, speak only as of today. Noble does not intend, and does not assume, any obligations to update any forward-looking statements contained herein, except as may be required by law or the rules of the New York Stock Exchange or Nasdaq Copenhagen. All subsequent written and oral forward-looking statements attributable to Noble or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements referred to above and contained in this announcement, including any attachment hereto.

View original content:https://www.prnewswire.co.uk/news-releases/noble-corporation-plc-announces-changes-to-its-share-capital-including-share-repurchases-for-the-month-of-november-2024-302318998.html

Advertisement